Compare OLP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | REPL |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 454.6M |
| IPO Year | 1995 | 2018 |
| Metric | OLP | REPL |
|---|---|---|
| Price | $24.42 | $15.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $26.75 | $5.67 |
| AVG Volume (30 Days) | 76.0K | ★ 7.4M |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | N/A |
| P/E Ratio | $24.53 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $1.50 |
| 52 Week High | $25.88 | $15.71 |
| Indicator | OLP | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 60.32 |
| Support Level | $24.40 | $9.01 |
| Resistance Level | $25.00 | $15.71 |
| Average True Range (ATR) | 0.46 | 1.17 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 97.83 | 77.95 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.